EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal Cancer Consortium Study

Deirdre J Cohen iD, Judith D Goldberg iD, Lawrence Leichman, Tsivia Hochman, Elliot Newman, Kevin Du, Alec Megibow, Paul Oberstein, Raed Al-Rajabi, Aaron J Scott, Tanios Bekaii-Saab, Wells A Messersmith und 1 weitere

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf271 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Oncologist, 2025. Verfasst von Deirdre J Cohen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, United States. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Adenocarcinoma, Perioperative Care, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NCI Cancer Center, NYU Grossman School of Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Surgical resection without visible or residual microscopic disease (R0 resection) is known as the optimal path to cure localized pancreatic cancer (PDAC). Neoadjuvant therapy (NAT) is used to improve R0 resection rates; however, the optimal regimen is unclear. We assessed the safety and efficacy of peri-operative gemcitabine/nab-paclitaxel (GEM/NAB) and pre-operative stereotactic body radiotherapy (SBRT) in patients with resectable (R-PDAC) and borderline resectable PDAC (BR-PDAC). Patients and Methods This was a prospective, multicenter single arm phase 2 study in patients with R-PDAC and BR-PDAC. Patients received three cycles of GEM/NAB prior to SBRT followed by surgery and three cycles of adjuvant GEM/NAB. Primary endpoint was R0 surgical resection rate in each cohort. Secondary endpoints included safety and overall survival (OS).

Results

Eighty-six patients consented and following radiologic screening, 49 were enrolled into two cohorts: R-PDAC (n = 20) and BR-PDAC (n = 29) between June 2016 and April 2021. Seventy percent of R-PDAC (14/20) and 55.2% of BR-PDAC patients (16/29) completed all NAT. Eleven R-PDAC (55.0%) and 11 BR-PDAC patients (37.9%) underwent surgical resection. Nine R-PDAC (45.0%) and 9 BR-PDAC patients (31.0%) had R0 resections. The median OS for R-PDAC and BR-PDAC patients with R0 resections was 22 months (95% CI: 17.7 months-NA) and 39 months (95%CI: 13.21 months-NA), respectively.

Conclusion

While the trial failed to meet one of its primary objectives as only 45% of R-PDAC patients had an R0 resection, the objective of 30% R0 resection for the BR-PDAC group was met. NAT should be part of current therapeutic strategies for BR-PDAC; however, our trial does not answer what is the best NAT for BR-PDAC. Trial Registration NCT02723331

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsAdenocarcinomaPerioperative CareAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleAgedMiddle AgedProspective StudiesDeoxycytidineGemcitabineNeoadjuvant TherapyRadiosurgeryAdultAged, 80 and overPaclitaxelAlbumins

Stichwörter der Autor:innen

R0 resectionneoadjuvantpancreatic cancerstereotactic body radiotherapy

Substanzen

DeoxycytidineGemcitabine130-nm albumin-bound paclitaxelPaclitaxelAlbumins

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, United States.
  • Division of Biostatistics, Department of Population Health, NYU Grossman School of Medicine, New York, NY, 10016, United States.
  • Division of Hematology and Oncology, Perlmutter Cancer Institute, NYU Langone Health, New York, NY, 10016, United States.
  • Division of Surgical Oncology, Northwell Health Lenox Hill Hospital, New York, NY, 10021, United States.
  • Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, 06519, United States.
  • Division of Radiology, NYU Grossman School of Medicine, New York, NY, 10016, United States.

ORCID-Profile: Deirdre J Cohen, Judith D Goldberg

Förderung

  • NCI NIH HHS
  • NCI Cancer Center
  • NYU Grossman School of Medicine

Zitieren

APA

Cohen, D. J., Goldberg, J. D., Leichman, L., Hochman, T., Newman, E., Du, K., Megibow, A., Oberstein, P., Al-Rajabi, R., Scott, A. J., Bekaii-Saab, T., Messersmith, W. A., & Weekes, C. (2025). Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal Cancer Consortium Study. The Oncologist. https://doi.org/10.1093/oncolo/oyaf271

Vancouver

Cohen DJ, Goldberg JD, Leichman L, Hochman T, Newman E, Du K, et al. Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal Cancer Consortium Study. The Oncologist. 2025. doi:10.1093/oncolo/oyaf271

BibTeX
@article{Cohen2025,
  author = {Cohen, Deirdre J and Goldberg, Judith D and Leichman, Lawrence and Hochman, Tsivia and Newman, Elliot and Du, Kevin and Megibow, Alec and Oberstein, Paul and Al-Rajabi, Raed and Scott, Aaron J and Bekaii-Saab, Tanios and Messersmith, Wells A and Weekes, Colin},
  title = {Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal Cancer Consortium Study},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf271}
}
Kostenlos starten →